Drugs / NFS-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05820152 | Aug 2023 → Jun 2024 | Leber hereditary optic neuropathy | Neurophth Therapeutics Inc | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-01-19 | Neurophth Therapeutics Inc | NFS-02！纽福斯眼科体内基因治疗新药获FDA孤儿药认定 neurophth.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NFS-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05820152 ↗ |
| Route | Intravitreal | “receive a single unilateral intravitreal (IVT) injection of NFS-02” NCT05820152 ↗ |